Renephra
Reducing heart failure admissions using community based transdermal fluid removal
- Funding £99,079
- Competition Reducing Pressure on Urgent & Emergency Care
- Competition Date Autumn 2015
- Local AHSN Greater Manchester AHSN
- Website http://renephra.com/
- Key Contact Idalia Dawidowska
- Status Proof of Concept
-
Technology Medical Devices
5% of emergency medical admissions to hospital in the UK are caused by heart failure and 90% of those are related to fluid overload. Treatment resistant fluid overload in heart failure requires hospital administration of intravenous diuretics. This is costly and related to risks such as kidney injury. Renephra transdermal technology offers gentle treatment that can be applied at home using existing community nurses services, reducing risk of complications, improving quality of life and reducing hospital admissions.
Comments are closed.